GlassScriptPhysician profile
Cody Miller
NPI 1871298448
$2,723.28
in general payments reported to CMS, 2019-2025
19 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $75.56 · 2024: $718 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,676 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.37 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $402.46 | 2024-2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $343.65 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $315.91 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $285.39 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $284.80 | 2024-2025 | Fanapt |
| Corium, LLC | $258.34 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $220.85 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.10 | 2024-2025 | Caplyta |
| Abbvie INC. | $114.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.25 | 2025 | Cobenfy |
| Indivior INC. | $46.93 | 2024-2025 | Sublocade, Perseris |
| Lundbeck LLC | $39.37 | 2025 | Abilify Asimtufii, Rexulti |
| Genentech USA, INC. | $24.41 | 2024 | Ocrevus |
| Ucb, INC. | $19.33 | 2023 | Fintepla |
| Axsome Therapeutics, INC. | $18.09 | 2023 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.95 | 2023 | Soliris |
| Novo Nordisk INC | $17.50 | 2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $16.61 | 2025 | Qelbree |
| Neos Therapeutics, LP | $14.90 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.